Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and asymptomatic subjects, and their implication in cardio/cerebro-vascular disorders

Neurochemistry International

Volumn 56, Issue 1, 2010, Pages 177-182

  Ferreira, Cláudia N ^a,b,c   Carvalho, Maria G ^a   Fernandes, Ana P S M ^a   Lima, Luciana M ^a   Loures Valle, Andréia A ^d   Dantas, Julizar ^e   Janka, Zoltán ^f   Palotás, András ^g   Sousa, Marinez O ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Prefeitura Municipal de Belo Horizonte   (Brazil)

^c FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

^d Hospital Geral Socor   (Brazil)

^e PETROBRAS   (Brazil)

^f UNIVERSITY OF SZEGED   (Hungary)

^g Asklepios Med Private Practice and Research Center   (Hungary)

Author keywords

Apolipoprotein E; Cholesterol; Dyslipidemia; High density lipoprotein (HDL); Lipid profile; Low density lipoprotein (LDL); Polymorphism; Risk factors

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL, LDL; DNA MUTATIONAL ANALYSIS; DYSLIPIDEMIAS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REFERENCE VALUES; RISK FACTORS;

EID: 73649146520     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.09.016     Document Type: Article

References (53)

1. Akanji A.O., Suresh C.G., Fatania H.R., Al-Radwan R., and Zubaid M. Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in Arab patients with coronary heart disease. Metabolism 56 (2007) 484-490
2. Akanuma S., Ohtsuki S., Doi Y., Tachikawa M., Ito S., Hori S., Asashima T., Hashimoto T., Yamada K., Ueda K., Iwatsubo T., and Terasaki T. ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-β peptide (1-40) at the blood-brain barrier. Neurochem. Int. 52 6 (2008) 956-961
3. Al-Khedhairy A.A. Apolipoprotein E polymorphism in Saudis. Mol. Biol. Rep. 1 (2004) 257-260
4. Altamura C., Squitti R., Pasqualetti P., Tibuzzi F., Silvestrini M., Ventriglia M.C., Cassetta E., Rossini M., and Vernieri F. What is the ralationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia?. Eur. J. Neurol. 14 (2007) 679-682
5. Andrade F.M., Coimbra Jr. C.E.A., Santos R.V., Goicoechea A., Carnese F.R., Salzano F.M., and Hutz M.H. High heterogeneity of apolipoprotein E gene frequencies in South American Indians. Ann. Hum. Biol. 27 1 (2000) 29-34
6. Arai H., Yamamoto A., Matsuzawa Y., Saito Y., Yamada N., Oikawa S., Mabuchi H., Teramoto T., Sasaki J., Nakaya N., Itakura H., Ishikawa Y., Ouchi Y., Horibe H., Egashira T., Hattoru H., and Kita T. Polymorphisms of apolipoprotein E and methylenetetrahydrofolate reductase in the Japanese population. J. Atheroscler. Thromb. 14 (2007) 167-171
7. Azad N.A., Bugami M., and Loy-English I. Gender differences in dementia risk factors. Gend. Med. 4 (2007) 120-129
8. Balcerzyk A., Zak I., and Krauze J. Synergistic effects of apolipoprotein E gene epsilon polymorphism and some conventional risk factors on premature ischaemic heart disease development. Kardiol. Pol. 65 (2007) 1058-1065
9. Barbagallo C.M., Polizzi F., Severino M., Rizzo M., Vivona N., Onorato F., Caldarella R., Cefalù A.B., Noto D., Notarbartolo A., and Averna M.R. ApoE polymorphism in a small Mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size. Eur. J. Epidemiol. 17 (2001) 707-713
10. Bennet A.M., Angelantonio E., Ye Z., Wensley F., Dahlin A., Ahlbom A., Keavney B., Collins R., Wiman B., Faire U., and Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298 11 (2007) 1300-1311
11. Bertolini S., Pisciotta L., Di Scala L., Langheim S., Bellocchio A., Masturzo P., Canatafora A., Martini S., Averna M., Pes G., Stefanutti C., and Calandra S. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 174 (2004) 57-65
12. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., and Stroela B.C. Apolipoprotein E polymorphism and cardiovascular disease: a huge review. Am. J. Epidemiol. 155 (2002) 487-495
13. Evans D., and Beil F.U. The D9N,N29IS and S447X variants in the lipoprotein lipase (LPL) gene are not associated with type III hyperlipidemia. BMC Med. Genet. 8 56 (2007) 1-6
14. Fiegenbaum M., Andrade F.M., and Hutz M.H. Association between plasma lipid parameters and ApoC3 genotypes in Brazilian subjects: effect of gender, smoking and ApoE genotypes. Clin. Chim. Acta 380 (2007) 175-181
15. Foley S.M. Update on risk factors for atherosclerosis: the role of inflammation and apolipoprotein E. Medsurg. Nursing 14 1 (2005) 43-50
16. Forti N., Salazar L.A., Diament J., Giannini S.D., Hirata M.H., and Hirata R.D.C. Alterações genéticas e colesterolemia: recentes estudos Brasileiros. Arq. Bras. Cardiol. 80 5 (2003) 565-571
17. França E., Alves J.G.B., and Hutz M.H. Apolipoprotein E polymorphism and its association with serum lipid levels in Brazilian children. Hum. Biol. 76 2 (2004) 267-275
18. Friedewald W.T., Levy R.I., and Fredrickison D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifugue. Clin. Chem. 18 (1972) 499-552
19. Fuzikawa A.K., Peixoto S.V., Taufer M., Moriguchi E.H., and Lima-Costa M.F. Apolipoprotein E polymorphism distribution in an elderly Brazilian population: the Bambuí health and aging study. Braz. J. Med. Biol. Res. 40 (2007) 1429-1434
20. Giassakis G., Veletza S., Papanas N., Heliopoulos I., and Piperidou H. Apolipoprotein E and first-ever ischaemic stroke in Greek hospitalized patients. J. Int. Med. Res. 35 (2007) 127-133
21. Giuliano I.C.B., Coutinho M.S.S.A., Freitas S.F.T., Pires M.M.S., Zunino J.N., and Ribeiro R.Q.C. Serum lipids in school kids and adolescents from Florianópolis, SC, Brazil-healthy floripa 2040 study. Arq. Bras. Cardiol. 85 2 (2005) 85-91
22. Granér M., Kahri J., Varpula M., Salonen R.M., Nyyssönen K., Jauhiainen M., Nieminen M.S., Syvänne M., and Taskinen M.R. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 18 4 (2008) 271-277
23. Greenow K., Pearce N.I., and Ramji D.P. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 83 (2005) 329-342
24. Grönroos P., Raitakari O.T., Kähönen M., Hutri-Kähönen N., Marniemi J., Viikari J., and Lehtimäki T. Influence of apolipoprotein E polymorfism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The cardiovascular risk in young Finns study. Clin. Chem. Lab. Med. 45 5 (2007) 592-598
25. Grönroos P., Raitakari O.T., Kähönen M., Hutri-Kähönen N., Juonala M., Marniemi J., Viikari J., and Lehtimäki T. Relation of apolipoprotein E polymorphism to markers of early atherosclerotic changes in young Finns study. Circ. J. 72 (2008) 29-34
26. Heeren J., Beisiegel U., and Grewal T. Apolipoprotein E recycling. Implications for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 442-448
27. Hirsch-Reinshagen V., Burgess B.L., and Wellington C.L. Why lipids are important for Alzheimer disease?. Mol. Cell. Biochem. 326 (2009) 121-129
28. Humphries S.E., Talmud P.J., Hawe E., Bolla M., Day I.N.M., and Miller G.J. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 358 (2001) 115-119
29. Ineu M.L., Manenti E., Costa J.L.V., and Moriguchi E. HDL management: recent advances and perspectives beyond LDL reduction. Arq. Bras. Cardiol. 87 6 (2006) 788-794
30. Klasen E.C., Talmud P.J., Havekest L., Wit E., van der Kooij-Meiss E., Smit M., Hansson G., and Humphries S.E. A common restriction fragment length polymorphism of the human apolipoprotein E gene and its relationship to type III hyperlipidaemia. Hum. Genet. 75 3 (1987) 244-247
31. Kulminski A.M., Ukraintseva S.V., Arbeev K.G., Manton K.G., Oshima J., Martin G.M., Il'yasova D., and Yashin A.I. Health-protective and adverse effects of the apolipoprotein E ε2 allele in older men. J. Am. Geriatr. Soc. 56 (2008) 478-483
32. Lu R., Ito J., Iwamoto N., Nishimaki-Mogami T., and Yokoyama S. FGF-1 induces expression of LXRα and production of 25-hydroxycholesterol to upregulate the apoE gene in rat astrocytes. J. Lipid Res. 50 6 (2009) 1156-1164
33. Malavazi I., Abrão E.P., Mikawa A.Y., Landgraf V.O., and Costa P.I. Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status. Clin. Chem. Lab. Med. 42 5 (2004) 525-532
34. Medina-Urrutia A.X., Cardoso-Saldaña G.C., Zamora-González J., Liria Y.K., and Posadas-Romero C. Apolipoprotein E polymorphism is related to plasma lipids and apolipoproteins in Mexican adolescents. Hum. Biol. 76 4 (2004) 605-614
35. Mendes-Lana A., Pena G.G., Freitas S.N., Lima A.A., Nicolato R.L.C., Nascimento-Neto R.M., Machado-Coelho G.L.L., and Freitas R.N. Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study. Braz. J. Med. Biol. Res. 40 1 (2007) 49-56
36. Minihane A.M., Jofre-Monseny L., Olano-Martin E., and Rimbach G. Apo E genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc. Nutr. Soc. 66 2 (2007) 183-197
37. Mooijaart S.P., Berbée J.F.P., Heemst D.V., Havekes L.M., Craen A.J.M., Slagboom P.E., Rensen P.C.N., and Westendorp R.G.J. Apo E plasma level and risk of cardiovascular mortality in old age. PLOS Med. 3 6 (2006) 874-883
38. Mozas P., Castillo S., Reyes G., Tejedor D., Civeira F., Garcia-Alvarez I., Puzo J., Cenarro A., Alonso R., Mata P., and Pocovi M. Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. Am. Heart J. 145 (2003) 999-1005
39. National Cholesterol Education Program. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 19 (2001) 2486-2497
40. Pitsavos C., Choumerianou D.M., Skoumas J., Maumus S., Stefanadis C., Dedoussis G.V.Z., and Visvikis-Siest S. Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clin. Exp. Med. 5 (2005) 196-201
41. Saidi S., Slamia L.B., Ammou S.B., Mahjoub T., and Almawi W.Y. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels. J. Stroke Cerebrovasc. Dis. 16 4 (2007) 160-166
42. Sepetiba R.J.C., Andrade J., Hirata R.D.C., Sepetiba C.R.G., Nakamura Y., Matsumoto L.O., Cavalli S.A., and Bertolami M.C. Lipoprotein lipase PvuII polymorphism is associated with variations in serum lipid levels in non-diabetic pregnant women. Braz. J. Med. Biol. Res. 40 (2007) 919-926
43. Soufi M., Sattler A.M., Maisch B., and Schaefer J.R. Molecular mechanisms involved in atherosclerosis. Herz 27 (2002) 637-648
44. Sousa M.O., Corbella E., Alía P., Cámara J., Castro M.J., Pintó X., and Navarro M.A. Ausencia de asociación entre el genotipo de la apolipoproteína E y la respuesta al tratamiento con estatinas en los pacientes con episodios isquémicos agudos. Med. Clin. (Barc.) 11 (2008) 401-404
45. Souza D.R.S., Campos B.F., Arruda E.F., Yamamoto L.J., Trindade D.M., and Tognola W.A. Influence of the polymorphism of apolipoprotein E in cerebral vascular disease. Arq. Neuropsiquiatr. 61 1 (2003) 7-13
46. Souza D.R.S., Nakachima L., Biagioni R.B., Nakazone M.A., Pinhel M.A.S., Trindade D.M., Mafra V.T., Tácito L.H.B., Martins J.F.V., Pinheiro Jr. S., and Brandão A.C. Relevance of apolipoprotein E4 for the lipid profile of Brazilian patients with coronary artery disease. Braz. J. Med. Biol. Res. 40 2 (2007) 189-197
47. Svobodová H., Kucera F., Stulc T., Vrablík M., Amartuvshin B., Altannavch T.S., and Ceska R. Apolipoprotein E gene polymorphism in the Mongolian population. Folia Biol. (Praha) 53 (2007) 138-142
48. Tavintharan S., Lim S.C., Chan Y.H., and Sum C.F. Apolipoprotein E genotypes affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diab. Obes. Metab. 9 (2007) 81-86
49. Takei N., Miyashita A., Tsukie T., Arai H., Asada T., Imagawa M., Shoji M., Higuchi S., Urakami K., Kakita A., Takahashi H., Tsuji S., Kanazawa I., Ihara Y., Odani S., Kuwano R., and the Japanese Genetic Study Consortium for Alzheimer Disease. Genetic association study on in and around the ApoE in late-onset Alzheimer disease in Japanese. Genomics 93 (2009) 441-448
50. Topic A., Kalimanovska V.S., Zeljkovic A., Vekic J., and Ivanovic Z.J. Gender-related effect of apo E polymorphism on lipoprotein particle sizes in the middle-aged subjects. Clin. Biochem. 41 (2008) 361-367
51. Tsukamoto K., Watanabe Y., Matsushima T., Kjnoshjta M., Kato H., Hashimoto Y., Kurokawa K., and Teramoto T. Determination by PCR-RFLP of apo E genotype in a Japanese population. J. Lab. Clin. Med. 121 4 (1992) 598-602
52. Tziakas D.N., Chalikias G.K., Antonoglou C.O., Veletza S., Tentes I.K., Kortsaris A.X., Hatseras D.I., and Kaski J.C. Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J. Am. Coll. Cardiol. 48 (2006) 2471-2481
53. Wiegman A., Sigebrabds E.J.G., Rodenburg J., Defesche J.C., Jongh S., Baker H.D., and Kastelein J.J.P. The apolipoprotein ε4 allele confers additional risk in children with familial hypercholesterolemia. Pediatr. Res. 53 6 (2003) 1008-1012